REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q1 P&L / Income Statement

REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q1 P&L / Income Statement

Income statement for 2026-01-01 through 2026-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

3,605,400,000 US dollars

Cost of revenue (calculated)

669,400,000 US dollars

Gross profit (calculated)

2,936,000,000 US dollars

Operating expenses (calculated)

2,293,100,000 US dollars

Income from operations

642,900,000 US dollars

Total other income (expense)

188,300,000 US dollars

Income before income taxes

831,200,000 US dollars

Income tax expense

104,000,000 US dollars

Net income

727,200,000 US dollars

Lynozyfic

11,200,000 US dollars

Other products

31,300,000 US dollars

EYLEA HD And EYLEA - UNITED STATES

941,500,000 US dollars

EYLEA HD - UNITED STATES

468,400,000 US dollars

Evkeeza - UNITED STATES

45,700,000 US dollars

EYLEA Net Product Sales - UNITED STATES

473,100,000 US dollars

Libtayo - UNITED STATES

286,100,000 US dollars

Libtayo - Rest Of World

152,100,000 US dollars

Praluent - UNITED STATES

66,600,000 US dollars

Undisclosed (calculated)

1,129,400,000 US dollars

Cost of goods sold, collaboration and contract manufacturing

669,400,000 US dollars

Research and development

1,543,500,000 US dollars

Acquired in-process research and development

101,900,000 US dollars

Selling, general, and administrative

647,700,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.